Teva announced the launch of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Tablets, the generic version of Daiichi Sankyo‘s Tribenzor, and Amlodipine and Olmesartan Medoxomil Tablets, the generic version of Daiichi Sankyo’s Azor.
Tribenzor combines an angiotensin II receptor blocker (ARB) + dihydropyridine calcium channel blocker (CCB) + thiazide diuretic. It is indicated to treat hypertension but not for initial therapy. Azor combines a CCB + ARB and is indicated for hypertension.
Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle. Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to reduce peripheral vascular resistance and reduce blood pressure. Hydrochlorothiazide affects renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.
Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Tablets are available as 20mg/5mg/12.5mg, 40mg/5mg/12.5mg, 40mg/5mg/25mg, 40mg/10mg/12.5mg, and 40mg/10mg/25mg strengths in 30- and 90-count bottles.
Amlodipine and Olmesartan Medoxomil Tablets are available as 5mg/20mg, 5mg/40mg, 10mg/20mg, and 10mg/40mg strengths in 30- and 90-count bottles.
For more information call (888) 838-2872 or visit TevaGenerics.com.